FDA Advisory Panel To Review Capricor's Deramiocel BLA In DMD

Capricor Therapeutics said the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet to review its Biologics License Application for Deramiocel in Duchenne muscular dystrophy. The announcement signals a key regulatory milestone, but it does not indicate an approval decision. The news is important for CAPR and the biotech sector, though the immediate market impact is likely limited until the committee outcome is known.

Analysis

Capricor Therapeutics said the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet to review its Biologics License Application for Deramiocel in Duchenne muscular dystrophy. The announcement signals a key regulatory milestone, but it does not indicate an approval decision. The news is important for CAPR and the biotech sector, though the immediate market impact is likely limited until the committee outcome is known.